

19 May 2022

Subject: Incidence and treatment of CLL and MCL

I am researching the incidence and treatment of CLL and MCL. I would greatly appreciate if you could answer the following questions.

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL)**
- **Mantle Cell Lymphoma (MCL)**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.**

Please see attached. The Trusts coding of diagnoses runs several months behind so we have included the most up to date data we have for these diagnoses between November 21 and January 2022.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab)**
- **Calquence (acalabrutinib)**
- **FCR (fludarabine + cyclophosphamide + rituximab)**
- **Gazyva (obinutuzumab) + chlorambucil**
- **Imbruvica (ibrutinib)**
- **Venclexta (venetoclax)**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab)**
- **Venclexta (venetoclax) + rituximab**
- **Zydelig (idelalisib) + rituximab**
- **Any other systemic anti-cancer therapy**

Unfortunately our haematology records are not electronic and to gather this data would be a manual trawl which would take longer than 18 hours. This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one

19 May 2022

or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab)**
- **Imbruvica (ibrutinib)**
- **Imbruvica (ibrutinib) + rituximab**
- **R-BAC (rituximab, bendamustine and cytarabine)**
- **R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)**
- **Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)**
- **Velcade (bortezomib) + chemotherapy**
- **Any other systemic anti-cancer therapy**
- **Stem cell transplant**
- **Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells**

Unfortunately our haematology records are not electronic and to gather this data would be a manual trawl which would take longer than 18 hours. This would exceed the costs limit specified in the FOI act. As Qu 2.

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

There are no open trials at present for CLL.

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

There are no open trials at present for MCL.